Insmed Inc

INSM remains in a Stage 2 Advancing corrective reset with a confirmed Momentum Breakout and rising EMAs supporting a bullish medium-term outlook. However, price is extended above the 9/21 EMA cluster with overbought RSI and elevated Options Score, suggesting caution. We recommend stalking for a pullback into rising 9/21 EMA support for a selective entry in line with the speculative strategy.

• ↑Q1 2026 Brinsupre sales reached $350M with 7,800 new patients
• ↑2026 revenue forecast at $1B driven by expanding market access
• ↓Negative earnings yield and weak profitability factors suggest overvaluation